Study on the correlation of Napsin-A expression and EGFR genes in non-small cell lung cancer tissue
-
摘要: 目的：探讨非小细胞肺癌（NSCLC）组织中 Napsin-A 表达与表皮生长因子受体（EGFR）基因的关系。方法采用免疫组织化学法检测89例肺腺鳞癌组织中 Napsin-A 的表达情况，并用 ARMS 试剂盒检测上述组织中 EGFR 基因的表达情况，分析 Napsin-A 的表达与 EGFR 基因的关系。结果在 NSCLC 组织中，腺癌和鳞癌的 Napsin-A 阳性率分别为96．2％和5．6％，两者比较差异有统计学意义。肺腺癌组织中，EGFR 基因突变率为54．7％，而 Napsin-A 表达阳性者的突变率高达100．0％；肺鳞癌组织中，EGFR 基因突变率为5．6％，而 Napsin-A 表达阳性者的突变率为50．0％，两者比较，差异有统计学意义。结论Napsin-A 在肺腺癌组织中高表达，且在腺鳞癌中表达阳性者 EGFR 基因突变率较高，Napsin-A 表达阳性者可建议行 EGFR 基因检测。Abstract: Objective To explore the relationship between Napsin-A expression and epider-mal growth factor receptor (EGFR)genes in non-small cell lung cancer (NSCLC)tissue.Methods Napsin-A expression in 89 adenosquamous carcinoma tissues of the lung was detected by immunohisto-chemistry,and the expression of EGFR genes in the tissues above was also detected by ARMS kit.The relationship between Napsin-A expression and EGFR was analyzed.Results The Napsin-A positive rates of adenocarcinoma and squamous carcinoma in NSCLC tissue were 96.2% and 5.6%,respec-tively,and there was statistical significance between them.The mutation rate of EGFR gene in lung adenocarcinoma tissue was 54.7%,while that of the patients with positive Napsin-A expression came up to 100.0%.The mutation rate of EGFR gene in lung squamous tissue was 5.6%,while that of the patients with positive Napsin-A expression came up to 50.0%,in which significant difference was presented by comparison to them.Conclusion Napsin-A is highly expressed in lung adenocarcinoma tissue,and the EGFR mutation rate of patients with positive expression in adenosquamous carcinoma is also high.Hence,for the patients with positive Napsin-A expression,it should be recommended to de-tect EGFR genes.
-
-
Yamashita Y, Nagasaka T, Naiki-Ito A. Napsin A is a specific marker for ovarian clear cell adenocarcinoma [J]. Modern Pathology, 2014. Aulakh K S, Chisholm C D, Smith D A. TTF-1 and napsin A do not differentiate metastatic lung adenocarcinomas from primary esophageal adenocarcinomas:proposal of a novel staining panel [J]. ARCHIVES OF PATHOLOGY AND LABORATORY MEDICINE, 2013(8):1094. Oh M J, Choi J H, Kim I H. Detection of epidermal growth f actor receptor in the serum of patients with cervical carcinoma [J]. Clinical Cancer Research, 2000, (12):4760. 李连弟, 鲁凤珠, 张思维. 中国恶性肿瘤死亡率 20 年变化趋势和近期预测分析 [J]. 中华肿瘤杂志, 1997(1):3. Turner B M, Cagle P T, Sainz I M. Napsin A, a new marker for lung adenocarcinoma, is complementary and more sensitive and specific than thyroid transcription factor 1 in the differential diagnosis of primary pulmonary carcinoma:evalua-tion of 1674 cases by tissue microarray [J]. ARCHIVES OF PATHOLOGY AND LABORATORY MEDICINE, 2012(2):163. Schauer-Vukasinovic V, Langen H, Giller T. Detection of im-munoreactive napsin A in human urine [J]. Biochimica et Biophysica Acta, 2001(1):51. Lim S H, Lee J Y, Sun J M. Comparison of clinical out-comes following gefitinib and erlotinib treatment in non-small-cell lung cancer patients harboring an epidermal growth factor receptor mutation in either exon 19 or 21 [J]. JOURNAL OF THORACIC ONCOLOGY, 2014(4):506. Hwang K E, Kwon S J, Kim Y S. Effect of simvastatin on the resistance to EGFR tyrosine kinase inhibitors in a non-small cell lung cancer with the T790Mmutation of EGFR [J]. Experimental Cell Research, 2014(2):288.
计量
- 文章访问数: 342
- HTML全文浏览量: 39
- PDF下载量: 1
下载:
苏公网安备 32100302010246号